Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 3/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12583871 | 0.86 | KMT2A (0.54) | ACLYKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL22021594 | 0.84 | ACLY (0.55) | ACLYKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL988193 | 0.82 | SLC6A4 (0.53) | ACLYKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22004299 | 0.77 | ACLY (0.59) | ACLYRXFP1PHGDHGFER | |
| SCHEMBL22021593 | 0.77 | ACLY (0.58) | ACLYKMT2AMEN1RXFP1GFER | |
| SCHEMBL22004306 | 0.76 | ACLY (0.49) | ACLYKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL22022199 | 0.76 | RXFP1 (0.59) | ACLYKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22004199 | 0.74 | ACLY (1.00) | ACLY | |
| SCHEMBL22021591 | 0.74 | KMT2A (0.46) | ACLYKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL12585250 | 0.72 | PHGDH (0.68) | KMT2AMEN1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885KMT2A 1976/4885MEN1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.